DCF Advisers’s Matinas BioPharma MTNB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
– Sell
-206
Closed -$156K – 81
2021
Q4
$156K Hold
206
– – 0.06% 70
2021
Q3
$201K Sell
206
-309
-60% -$200K 0.09% 78
2021
Q2
$299K Sell
515
-18
-3% -$11.6K 0.11% 83
2021
Q1
$420K Buy
533
+126
+31% +$127K 0.18% 82
2020
Q4
$415K Sell
407
-329
-45% -$229K 0.17% 75
2020
Q3
$423K Sell
736
-16
-2% -$9.5K 0.22% 65
2020
Q2
$436K Sell
752
-75
-9% -$43.1K 0.24% 59
2020
Q1
$372K Buy
827
+462
+127% +$418K 0.24% 52
2019
Q4
$622K Hold
365
– – 0.39% 48

Other funds holding MTNB

DCF Advisers's MTNB Position: Q1 2022 in Review

DCF Advisers sold out of Matinas BioPharma (MTNB) in Q1 2022, closing a stake of 206 shares — an estimated $156K sold.

DCF Advisers first reported a position in MTNB in Q4 2019 and held it in 9 quarters. The position peaked at $622K in Q4 2019. 54 funds tracked by Wall St. Rank hold MTNB as of Q1 2022.

  • DCF Advisers reported no remaining Matinas BioPharma position as of Q1 2022 after selling out during the quarter.
  • DCF Advisers sold 206 Matinas BioPharma shares in Q1 2022, an estimated $156K.
  • DCF Advisers first reported a position in Matinas BioPharma in Q4 2019 and held it in 9 quarters.
  • DCF Advisers's Matinas BioPharma position peaked at $622K in Q4 2019.
  • 54 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2022.

Based on DCF Advisers's 13F filing for Q1 2022, filed 13 May 2022.